Tags

Type your tag names separated by a space and hit enter

Fenofibrate decreased microalbuminuria in the type 2 diabetes patients with hypertriglyceridemia.
Lipids Health Dis. 2020 May 23; 19(1):103.LH

Abstract

BACKGROUND

This study was to research the efficacy of fenofibrate in the treatment of microalbuminuria in the patients with type 2 diabetes mellitus (T2DM) and hypertriglyceridemia.

METHODS

Type 2 diabetic patients (56) with microalbuminuria and hypertriglyceridemia aged 30 to 75 were randomly divided into the fenofibrate treatment group(n = 28) and the control group (n = 28) for 180 days. Urinary microalbumin /creatinine ratio (UACR) and other metabolic parameters were compared at baseline, during treatment and after treatment.

RESULTS

After 180 days, the reduction of level of fasting blood glucose (FBG) and glycosylated hemoglobin (HbA1c) between two groups showed no difference. In the treatment group, uric acid (UA) (296.42 ± 56.41 vs 372.46 ± 72.78), triglyceride (TG) [1.51(1.17, 2.06) vs 3.04(2.21, 3.29)], and UACR [36.45 (15.78,102.41) vs 129.00 (53.00, 226.25)] were significantly decreased compared with the baseline. The high-density lipoprotein cholesterol (HDL-C) levels were significantly increased (1.22 ± 0.26 vs 1.09 ± 0.24) compared with the baseline. The decrease in UACR [- 44.05(- 179.47, - 12.16) vs - 8.15(- 59.69, 41.94)]in treatment group was significantly higher compared with the control group. The decrease in UACR was positively associated with the decreases in TG (r = 0.447, P = 0.042) and UA (r = 0.478, P = 0.024) after fenofibrate treatment.

CONCLUSION

In the patients with hypertriglyceridemia and type 2 diabetes mellitus, fenofibrate can improve microalbuminuria and do not increase the deterioration of glomerular filtration rate.

TRIAL REGISTRATION

ClinicalTrials.gov identifier: NCT02314533, 2014.12.9.

Authors+Show Affiliations

Department of Endocrinology, Beijing Chao-Yang Hospital, Capital Medical University, 8 Gongren Tiyuchang Nanlu, Chaoyang District, Beijing, 100020, P. R. China.Department of Endocrinology, Beijing Chao-Yang Hospital, Capital Medical University, 8 Gongren Tiyuchang Nanlu, Chaoyang District, Beijing, 100020, P. R. China.Department of Endocrinology, Beijing Chao-Yang Hospital, Capital Medical University, 8 Gongren Tiyuchang Nanlu, Chaoyang District, Beijing, 100020, P. R. China. drwg6688@126.com.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32446306

Citation

Sun, Xiaomeng, et al. "Fenofibrate Decreased Microalbuminuria in the Type 2 Diabetes Patients With Hypertriglyceridemia." Lipids in Health and Disease, vol. 19, no. 1, 2020, p. 103.
Sun X, Liu J, Wang G. Fenofibrate decreased microalbuminuria in the type 2 diabetes patients with hypertriglyceridemia. Lipids Health Dis. 2020;19(1):103.
Sun, X., Liu, J., & Wang, G. (2020). Fenofibrate decreased microalbuminuria in the type 2 diabetes patients with hypertriglyceridemia. Lipids in Health and Disease, 19(1), 103. https://doi.org/10.1186/s12944-020-01254-2
Sun X, Liu J, Wang G. Fenofibrate Decreased Microalbuminuria in the Type 2 Diabetes Patients With Hypertriglyceridemia. Lipids Health Dis. 2020 May 23;19(1):103. PubMed PMID: 32446306.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Fenofibrate decreased microalbuminuria in the type 2 diabetes patients with hypertriglyceridemia. AU - Sun,Xiaomeng, AU - Liu,Jia, AU - Wang,Guang, Y1 - 2020/05/23/ PY - 2019/12/28/received PY - 2020/03/31/accepted PY - 2020/5/25/entrez PY - 2020/5/25/pubmed PY - 2020/5/25/medline KW - Fenofibrate KW - Hypertriglyceridemia KW - Type 2 diabetes mellitus KW - Urinary albumin/creatinine ratio SP - 103 EP - 103 JF - Lipids in health and disease JO - Lipids Health Dis VL - 19 IS - 1 N2 - BACKGROUND: This study was to research the efficacy of fenofibrate in the treatment of microalbuminuria in the patients with type 2 diabetes mellitus (T2DM) and hypertriglyceridemia. METHODS: Type 2 diabetic patients (56) with microalbuminuria and hypertriglyceridemia aged 30 to 75 were randomly divided into the fenofibrate treatment group(n = 28) and the control group (n = 28) for 180 days. Urinary microalbumin /creatinine ratio (UACR) and other metabolic parameters were compared at baseline, during treatment and after treatment. RESULTS: After 180 days, the reduction of level of fasting blood glucose (FBG) and glycosylated hemoglobin (HbA1c) between two groups showed no difference. In the treatment group, uric acid (UA) (296.42 ± 56.41 vs 372.46 ± 72.78), triglyceride (TG) [1.51(1.17, 2.06) vs 3.04(2.21, 3.29)], and UACR [36.45 (15.78,102.41) vs 129.00 (53.00, 226.25)] were significantly decreased compared with the baseline. The high-density lipoprotein cholesterol (HDL-C) levels were significantly increased (1.22 ± 0.26 vs 1.09 ± 0.24) compared with the baseline. The decrease in UACR [- 44.05(- 179.47, - 12.16) vs - 8.15(- 59.69, 41.94)]in treatment group was significantly higher compared with the control group. The decrease in UACR was positively associated with the decreases in TG (r = 0.447, P = 0.042) and UA (r = 0.478, P = 0.024) after fenofibrate treatment. CONCLUSION: In the patients with hypertriglyceridemia and type 2 diabetes mellitus, fenofibrate can improve microalbuminuria and do not increase the deterioration of glomerular filtration rate. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02314533, 2014.12.9. SN - 1476-511X UR - https://www.unboundmedicine.com/medline/citation/32446306/Fenofibrate_decreased_microalbuminuria_in_the_type_2_diabetes_patients_with_hypertriglyceridemia L2 - https://lipidworld.biomedcentral.com/articles/10.1186/s12944-020-01254-2 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.